LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

Home・Akcijų sąrašas・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

47.35 1.41

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

46.91

Max

49.06

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-14M -130M
Pardavimai	-888K 143K
Pelno marža	-90,972.727
Darbuotojai	437
EBITDA	33K -129M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+71.42% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	258M 4.3B
Ankstesnė atidarymo kaina	45.94
Ankstesnė uždarymo kaina	47.35

Naujienos nuotaikos

By Acuity

26%

74%

52 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

30.39 / 33.46 Palaikymas ir pasipriešinimas

Crinetics Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-08 23:48; UTC

Pagrindinės rinkos jėgos

Shares of Sezzle and Vital Farms Rise on S&P SmallCap 600 Inclusion

2025-12-08 23:44; UTC

Rinkos pokalbiai

Perky Australian Dollar Looks to Extend Gains -- Market Talk

2025-12-08 23:42; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Uncertainty Over Econ, Earnings -- Market Talk

2025-12-08 23:13; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-08 23:13; UTC

Rinkos pokalbiai

Australian Inflation Expectations Highest Since Late 2023 -- Market Talk

2025-12-08 23:09; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Made a Hostile Bid for Warner After Netflix Deal. What Happens Next? -- WSJ

2025-12-08 22:46; UTC

Rinkos pokalbiai

Rio Tinto Building Low-Cost Lithium Business in Difficult Market -- Market Talk

2025-12-08 22:01; UTC

Rinkos pokalbiai

Miners Poised to Do Well in 2026 -- Market Talk

2025-12-08 22:00; UTC

Įsigijimai, susijungimai, perėmimai

Noble: Agreement With Borr Includes Sale of Noble Tom Prosser, Noble Mick O'Brien, Noble Regina Allen, Noble Resilient, Noble Resolute, Closing Expected in Early 2026 >NE

2025-12-08 22:00; UTC

Įsigijimai, susijungimai, perėmimai

Noble: Agreement With Borr Comprises $210M in Cash and $150M in Seller Notes >NE

2025-12-08 22:00; UTC

Įsigijimai, susijungimai, perėmimai

Noble: Agreement With Ocean Oilfield Drilling Anticipates the Sale of the Noble Resolve, Closing Is Expected in 2Q 2026, Upon Conclusion of Noble Resolve's Current Contract >NE

2025-12-08 22:00; UTC

Įsigijimai, susijungimai, perėmimai

Noble: To Sell Five Rigs to Borr Drilling Limited for $360M and One Rig to Ocean Oilfield Drilling for $64M in Cash >NE

2025-12-08 21:51; UTC

Rinkos pokalbiai

US-Canada Rate Spreads Narrow Sharply After Record Gap -- Market Talk

2025-12-08 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2025-12-08 21:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-12-08 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-08 21:38; UTC

Įsigijimai, susijungimai, perėmimai

Boeing Buys Company Responsible for Door Blowout. The Stock Rises. -- Barrons.com

2025-12-08 21:38; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Makes $77.9 Billion Hostile Bid for Warner After Netflix Struck Deal -- 7th Update

2025-12-08 21:36; UTC

Rinkos pokalbiai

Oil Oversupply to Show Up As Waterborne Stocks Land -- Market Talk

2025-12-08 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Will the Netflix-Warner Bros. Merger Go Through? It Depends on How You Define Market Share. -- Barrons.com

2025-12-08 21:12; UTC

Įsigijimai, susijungimai, perėmimai

These Stocks Moved the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

2025-12-08 21:08; UTC

Rinkos pokalbiai

Rosenberg Turns 'Outright Bullish' on Canada Dollar -- Market Talk

2025-12-08 20:38; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Netflix Co-CEOs Confident About Regulatory Approval for WBD Deal -- Market Talk

2025-12-08 20:26; UTC

Įsigijimai, susijungimai, perėmimai

These Stocks Are Moving the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

2025-12-08 20:18; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Netflix Isn't Looking to Make Cuts at Warner Bros. Discovery -- Market Talk

2025-12-08 20:07; UTC

Rinkos pokalbiai

Oil Futures Snap Three-Session Winning Streak -- Market Talk

2025-12-08 20:06; UTC

Rinkos pokalbiai

U.S. Natural Gas Pulls Back From Weather-Driven Highs -- Market Talk

2025-12-08 20:05; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-12-08 20:05; UTC

Rinkos pokalbiai

Deere Offers Sales Growth Forecast Through 2030 -- Market Talk

2025-12-08 20:01; UTC

Rinkos pokalbiai

Precious Metals Slip Ahead of Fed Decision -- Market Talk

Akcijų palyginimas

Kainos pokytis

Crinetics Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

71.42% į viršų

12 mėnesių prognozė

Vidutinis 80 USD 71.42%

Aukščiausias 108 USD

Žemiausias 45 USD

Remiantis 15 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Crinetics Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

15 ratings

Pirkti

Laikyti

Parduoti

Remiantis 15 analitikų, pateikusių Crinetics Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

30.39 / 33.46Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Rinkos nuotaikos

By Acuity

52 / 374 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.